Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment.
Noris M, Daina E, Remuzzi G.
Nephrol Dial Transplant. 2023 Feb 13;38(2):283-290. doi: 10.1093/ndt/gfab281.
A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.
Schena FP, Esposito P, Rossini M.
Int J Mol Sci. 2020 Jan 14;21(2):525. doi: 10.3390/ijms21020525.
Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.
Kovala M, Seppälä M, Räisänen-Sokolowski A, Meri S, Honkanen E, Kaartinen K.
Cells. 2023 Feb 23;12(5):712. doi: 10.3390/cells12050712.
Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V.
Kidney Int. 2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63. Epub 2012 Mar 28.
Membranoproliferative glomerulonephritis.
Alchi B, Jayne D.
Pediatr Nephrol. 2010 Aug;25(8):1409-18. doi: 10.1007/s00467-009-1322-7. Epub 2009 Nov 12.
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update.
Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Würzner R, Zipfel PF.
J Am Soc Nephrol. 2005 May;16(5):1392-403. doi: 10.1681/ASN.2005010078. Epub 2005 Mar 30.
Retinal findings in glomerulonephritis.
Mack HG, Colville DJ, Harraka P, Savige JA, Invernizzi A, Fraser-Bell S.
Clin Exp Optom. 2022 Jul;105(5):474-486. doi: 10.1080/08164622.2021.2003691. Epub 2021 Dec 8.
Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease.
Vernon KA, Pickering MC, Cook T.
Contrib Nephrol. 2011;169:198-210. doi: 10.1159/000314775. Epub 2011 Jan 20.
Mesangiocapillary glomerulonephritis.
D'Amico G, Ferrario F.
J Am Soc Nephrol. 1992 Apr;2(10 Suppl):S159-66. doi: 10.1681/ASN.V210s159.
Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy: Randomized, Double-Blind Clinical Trial.
Bomback AS, Herlitz LC, Kedia PP, Petersen J, Yue H, Lafayette RA; ACCOLADE Study Group.
J Am Soc Nephrol. 2025 Mar 1;36(3):487-499. doi: 10.1681/ASN.0000000526. Epub 2024 Oct 11.
